Under the expanded agreement, Abbott will develop a PCR test for use on the Abbott m2000rt™ instrument to screen non-small cell lung cancer tumors for the expression of the PRAME antigen. PRAME is a preferentially expressed antigen of melanoma that is expressed in 69% of non-small cell lung cancer cases, as well as in a wide variety of cancer types, including melanoma, breast, ovarian, and bladder cancer, with limited expression in normal cells.
Today’s announcement is an expansion of a cancer-biomarker collaboration the two companies inked in 2009 (#msg-39511634)